Skip to main content
SpringerLink
Log in

Etoposide: current status and future perspectives in the management of malignant neoplasms

  • Session 3: Clinical Trials and Applications
  • Etoposide, Topoisomerase II, Malignant Neoplasms
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstracts

Etoposide has demonstrated highly significant clinical activity against a wide variety of neoplasms, including germ-cell malignancies, small-cell lung cancer, non-Hodgkin's lymphomas, leukemias, Kaposi's sarcoma, neuroblastoma, and soft-tissue sarcomas. It is also one of the important agents in the preparatory regimens given prior to bone marrow and peripheral stem-cell rescue. Despite its high degree of efficacy in a number of malignancies, the optimal dose, schedule, and dosing form remain to be defined. It is possible that continuous or prolonged inhibition of the substrate, i.e., topoisomerase II, may be the key factor for the cytotoxic effects of etoposide. Clinical studies have shown the activity of etoposide to be schedule-dependent, with prolonged dosing, best accomplished by the oral dosing form, offering a therapeutic advantage. This benefit awaits validation by prospective randomized studies, some of which are in progress. Recent clinical investigations have focused on the use of etoposide in combination with (a) cytokines to ameliorate myelosuppression, the dose-limiting toxicity of etoposide; (b) agents such as cyclosporin A and verapamil to alter the p-glycoprotein (mdr 1) function; and (c) topoisomerase I inhibitors to modulate the substrate upon which it acts. There is continued interest in the development of etoposide to its maximal clinical dimensions and in the examination of alternative biochemical and mechanistic approaches to further our understanding of this highly active agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al (1985) Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 312:692–700

    Google Scholar 

  2. Williams SD, Birch R, Einhorn LH, et al (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435–1441

    Google Scholar 

  3. Clark P, Cottier B, Joel S, et al (1991) Two prolonged schedules of single agent oral etoposide of differing duration and dose in patients with untreated small cell lung cancer (SCLC) (abstract 931). Proc Am Soc Clin Oncol 10:268

    Google Scholar 

  4. Johnson DH, Hainsworth JD, Hande KR, et al (1991) Current status of etoposide in the management of small cell lung cancer. Cancer 67:231–233

    Google Scholar 

  5. Waits TM, Johnson DH, Hainsworth JD, et al (1992) Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 10:292–296

    Google Scholar 

  6. Bender RA, Anderson T, Fisher RI, et al (1978) Activity of epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin's lymphoma. Am J Hematol 5: 203–209

    Google Scholar 

  7. Taylor RE, McElwain TJ, Barrett A, et al (1982) Etoposide as a single agent in relapsed advanced lymphoma. A phase II study. Cancer Chemother Pharmacol 7:175–177

    Google Scholar 

  8. Laubenstein LJ, Krigel RL, Odejnyk CM, et al (1984) Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2:115–130

    Google Scholar 

  9. Horowitz ME (1989) Ewing's sarcoma: current status of diagnosis and treatment. Oncology 3:101–106

    Google Scholar 

  10. Carli M, Perilongo G, diMontezemolo LC, et al (1987) Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 71:525–527

    Google Scholar 

  11. Kelsen DP, Magill G, Cheng E, et al (1982) Phase II trial of etoposide in the treatment of upper gastrointestinal malignancies (abstract). Proc Am Soc Clin Oncol 1:96

    Google Scholar 

  12. Kuhrie H, Meerpohl HG, Lenaz L, et al (1988) Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol 7:A257

    Google Scholar 

  13. Slevin ML, Clark PI, Joel SP, et al (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333–1340

    Google Scholar 

  14. Carney DN, Grogan L, Smit EF, et al (1990) Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 17 [Suppl 2]:49–53

    Google Scholar 

  15. Johnson DH, Greco FA, Strupp J, et al (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613–1617

    Google Scholar 

  16. Smyth RD, Pfeffer M, Scalzo A, et al (1985) Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12 [Suppl 2]: 48–51

    Google Scholar 

  17. Smit EF, Carney DN, Harford P, et al (1989) A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631–633

    Google Scholar 

  18. Greco F (1991) Chronic oral etoposide. Cancer 67:303–309

    Google Scholar 

  19. Eagan RT, Carr DT, Fryak S, et al (1976) VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer. Cancer Treat Rep 60:949–951

    Google Scholar 

  20. Tucker RD, Ferguson A, Van Wyk C, et al (1978) Chemotherapy of small cell carcinoma of the lung with VP-16-213. Cancer 141:1710–1714

    Google Scholar 

  21. Matsui Y, Oshima S, Kado M, et al (1987) Phase II study of oral VP-16-213 in small cell lung cancer. Cancer 60:2882–2885

    Google Scholar 

  22. Hansen M, Hirsch F, Dombernowsky P, et al (1977) Treatment of small cell anaplastic carcinoma of the lung with oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-4-(4,6-O-ethylidene-β-d-glycopryanoside). Cancer 40:633–637

    Google Scholar 

  23. Cavilli F, Sonntag RW, Jungi F, et al (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473–475

    Google Scholar 

  24. Greco FA, Garrow GC, Johnson DH, et al (1992) Prolonged continuous infusion of low-dose etoposide in responsive neoplasm: preliminary phase I/II results. Proc Am Soc Clin Oncol 11:115

    Google Scholar 

  25. Einhorn LH, Greco A, Wampler G, et al (1987) Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin and vincristine in the treatment of small cell lung cancer. Proc Am Soc Clin Oncol 6:168

    Google Scholar 

  26. Evans WK, Feld R, Murray N, et al (1987) Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451–458

    Google Scholar 

  27. Natalir RB, Shank B, Hilaris BS, et al (1985) Combination cyclophosphamide, Adriamycin and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer. Am J Med 79:303–308

    Google Scholar 

  28. Woods RL, Levi JA (1984) Chemotherapy for small cell lung cancer (SCLC2w): a randomized study of maintenance therapy with cyclophosphamide, Adriamycin and vincristine (CAV) after remission induction therapy with cisplatinum (CIS-DDP), VP-16-213 and radiotherapy. Proc Am Soc Clin Oncol 3:214

    Google Scholar 

  29. Aisner J, Whitacre MY, Abrams J, et al (1986) Adriamycin, cytoxan, etoposide (ACE) and platinum, adriamycin, cytoxan, etoposide (PACE) for small cell carcinoma of the lung. Semin Oncol 13:54–62 (suppl 3)

    Google Scholar 

  30. Aisner J, Whitacre MY, Budman DR, et al (1992) Cisplatin, doxorubicin, cyclosphosphamide and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemother Pharmacol 29:435–438

    Google Scholar 

  31. Ruckdeschel JC (1991) Etoposide in the management of non-small cell lung cancer. Cancer 67:250–253

    Google Scholar 

  32. Niederle N, Ostermann J, Achterrath W, et al (1991) Etoposide in patients with previously untreated non-small cell lung cancer: a phase I study. Cancer Chemother Pharmacol 28:59–62

    Google Scholar 

  33. Rosso R, Salvati F, Ardizzoni A, et al (1991) Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force. Cancer 66:130–134

    Google Scholar 

  34. Saxman S, Logie K, Stephens D, et al (1990) Phase II trial of daily oral etoposide in patients with surgically unresectable non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 9:238

    Google Scholar 

  35. Gatzcincier U, Neuhauss R, Heckmayr M (1991) Single agent oral etoposide in advanced NSCLC (chronic daily) and in elderly patients with SCLC (abstract) Lung Cancer 7 [Suppl]: 102

    Google Scholar 

  36. Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11:1179–1188

    Google Scholar 

  37. Grunberg SM, Crowley JJ, Livingston R, et al (1993) Treatment of stage IV non-small cell lung cancer (NSCLC) with long term administration of oral otoposide (E) and oral cyclophosphamide (C). A Southwest Oncology Group study. J Clin Oncol 11: 1598–1601

    Google Scholar 

  38. Walls J, Devore R, Hainsworth JD, et al (1991) Carboplatin (CBDCA) plus prolonged administration of oral etoposide (E) in the treatment of non-small cell lung cancer (NSCLC): a phase I/II trial (abstract). Proc Am Soc Clin Oncol 10:257

    Google Scholar 

  39. Newlands E, Bagshawe K (1977) Epipodophyllotoxin derivative (VP16-213) in malignant teratomas and choriocarcinomas (letter). Lancet II:87

    Google Scholar 

  40. Hainsworth JD, Greco FA, Williams SD, et al (1984) VP-16-213 in the treatment of refractory germinal neoplasms. In: Issel BF, Muggia FM, Carter SK (eds) Etoposide (VP-16). Current status and new developments, Academic Press (Harcourt Brace Iovanovich, Publishers) London, pp 233–243

    Google Scholar 

  41. Williams S, Einhorn L, Greco F, et al (1980) VP-16-213 salvage therapy for refractory germinals neoplasms. Cancer 46:2154–2158

    Google Scholar 

  42. Birch R, Williams S, Cone A, et al (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400–407

    Google Scholar 

  43. Einhorn LH, Williams SD, Loehrer PJ, et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors. A Southwestern Cancer Study Group protocol. J Clin Oncol 7:387–391

    Google Scholar 

  44. Loehrer PJ, Elson P, Johnson DH, et al (1991) A randomized trial of cisplatin plus etoposide with or without bleomycin in favorable prognosis disseminated germ cell tumors (abstract) Proc Am Soc Clin Oncol 10:169

    Google Scholar 

  45. Nichols C, Williams S, Loehrer P, et al (1991) Randomized study of cisplatin dose intensity in advanced germ cell tumors: a Southwestern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163–1172

    Google Scholar 

  46. Wheeler B, Loehrer P, Wiliams S, et al (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28–34

    Google Scholar 

  47. Loehrer PJ, Lauer R, Roth BJ, et al (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540–546

    Google Scholar 

  48. Stoter G, Sleijfer DT, Schornagel JH, et al (1993) BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 12:232

    Google Scholar 

  49. Nichols CR, Tricot G, Williams SD, et al (1989) Dose-intensive chemotherapy in refractory germ cell cancer — a phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932–939

    Google Scholar 

  50. Rosti G, Salvioni R, Pizzocaro G, et al (1990) High dose chemotherapy (HDC) with carboplatin (CBP) and VP-16 in germ cell tumors: the Italian experience. In: Dicke K, Armitage JO, Dicke-Evinger MJ (eds) Proceedings of the Fifth International Bone Marrow Transplant Symposium, Omaha, Nebraska, pp 186

  51. Bishop JF (1992) Etoposide in the treatment of acute leukemias. Semin Oncol 19 [Suppl 13]:33–38

    Google Scholar 

  52. Look AT, Dahl GV, Kalwinsky D, et al (1981) Effective remission induction of refractory childhood acute non-lymphocytic leukemia by VP-16-213 plus azacytidine. Cancer Treat Rep 65:995–999

    Google Scholar 

  53. Kalwinsky DK, Dahl GV, Mirro J, et al (1986) Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. Med Pediatr Oncol 14:245–250

    Google Scholar 

  54. Letendre L, Hinemann V, Hoagland C, et al (1985) Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Med Pediatr Oncol 13:232–234

    Google Scholar 

  55. Tschopp L, Fliedner VE von, Saufer C, et al (1986) Efficacy and clinical cross-resistances of a new combination therapy (AMSA/ VP16) in previously treated patients with acute non-lymphocytic leukemia. J Clin Oncol 4:318–324

    Google Scholar 

  56. Carella AM, Santini G, Giordano D, et al (1985) Idarubicin alone or in combination with cytarabine and etoposide (3+3+5 protocol) in acute non-lymphoblastic leukemia (letter) Leuk Res 9:631

    Google Scholar 

  57. Ho AD, Lipp T, Ehiger G, et al (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia — an active well tolerated regimen. J Clin Oncol 6:213–217

    Google Scholar 

  58. Lazzarino M, Morra E, Alessandrino EP, et al (1989) Treatment of relapsed or refractory acute myeloid leukemia in adults. Bone Marrow Transplant [Suppl] 4:121–123

    Google Scholar 

  59. Bishop JF, Joshua DE, Lowenthal RM, et al (1986) A phase I-II study of cytosine arabinoside, daunorubicin and VP16-213 in adult patients with acute non-lymphocytic leukemia. Aust NZ J Med 16:48–51

    Google Scholar 

  60. DeVita VT, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:891–895

    Google Scholar 

  61. Glick J, Tsiatis A, Schilsky R, et al (1991) A randomized phase III trial of MOPP/ABVD hybrid vs. sequential MOPP-ABVD in advanced Hodgkin's disease: preliminary results of the Intergroup Trial (abstract). Proc Am Soc Clin Oncol 10:A941

    Google Scholar 

  62. Bonadonna G, Zucali R, Monfardini S, et al (1975) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 36:252–259

    Google Scholar 

  63. Longo DL, Young RC, Wesley M, et al (1986) Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295–1306

    Google Scholar 

  64. Fox KA, Lippman SM, Cassady JR, et al (1987) Radiation therapy salvage of Hodgkin's, disease following chemotherapy. J Clin Oncol 5:544–549

    Google Scholar 

  65. Richards MA, Waxman JH, Ganesan TS, et al (1986) EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 18: 51–53

    Google Scholar 

  66. Longo DL, Duffey PL, Young RC, et al (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10: 210–218

    Google Scholar 

  67. Tseng A Jr, Jacobs C, Coleman CN, et al (1987) Third line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide and methotrexate. Cancer Treat Rep 71: 475–478

    Google Scholar 

  68. Pfreundschuh MG, Schoppe WD, Fuchss R, et al (1987) Lomustine, etoposide, vindesine and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine and decarbazine: a multicenter trial of the German Hodgkin's Study Group. Cancer Treat Rep 71: 1203–1207

    Google Scholar 

  69. Santoro A, Viviani SS, Valagussa P, et al (1986) CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 13: 23–26

    Google Scholar 

  70. Cervantes F, Reverter JC, Montserrat E, et al (1986) Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide and prednimustine. Cancer Treat Rep 70: 665–667

    Google Scholar 

  71. Hagemeister FBN, Tannir N, McLaughlin P, et al (1987) MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5: 556–561

    Google Scholar 

  72. Gribben JG, Linch DC, Singer CRJ, et al (1989) Successful treatment of refractory Hodgkin's disease by high dose combination chemotherapy and autologous bone marrow transplantation. Blood 73: 340

    Google Scholar 

  73. Yahalom J, Girlati S, Shank B, et al (1989) Total lymphoid irradiation, high dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Int J Radiat Oncol Biol Phys 17: 915

    Google Scholar 

  74. Fisher RI, Devita VT Jr, Hubbard SM, et al (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of Pro MACE and MOPP chemotherapy. Ann Intern Med 98: 304–309

    Google Scholar 

  75. Longo DL, DeVita VT Jr, Duffy PL, et al (1991) Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9: 25–38

    Google Scholar 

  76. Frederico M, Moretti G, Gobbi PG, et al (1991) ProMACE-CytaBOM vs. MACOP-B in intermediate and high-grade NHL. Preliminary results of a prospective randomized trial. Leukemia 5: 95–101

    Google Scholar 

  77. O'Reilly SE, Hoskins P, Kleins P, et al (1991) MACP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABD in Hodgkin's disease. Ann Oncol 2: 17–23

    Google Scholar 

  78. Fisher RI, Gaynor E, Dahlberg S, et al (1993) Comparison of a standard regimen (CHOPE) with three intensive chemotherapy programmes for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002–1006

    Google Scholar 

  79. Herzig RH (1991) High-dose etoposide and marrow transplantation. Cancer 67: 292–298

    Google Scholar 

  80. Spitzer GR, Cottler-Fox M, Torrisi J, et al (1989) Escalating doses of etoposide with a cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 4: 559–565

    Google Scholar 

  81. Horning SJ, Chao NJ, Negrin RS, et al (1991) The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol 2 [Suppl 1] 47–50

    Google Scholar 

  82. Freedman AS, Takvorian T, Anderson KC, et al (1990) Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment related mortality in 100 patients in sensitive relapse. J Clin Oncol 8: 784–791

    Google Scholar 

  83. Wilson WH, Bryant G, Bates S, et al (1991) Infusional etoposide (E), vincristine (O) and Adriamycin (H) with cyclophosphamide (C), prednisone (P) (EPOCH) and r-verapamil (RV) in relapsed lymphoma (abstract). Proc Am Soc Clin Oncol 10: 276

    Google Scholar 

  84. Beral V, Peterman TA, Berkelman RL, et al (1990) Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123

    Google Scholar 

  85. Shields P, Dawkins F, Holmlund J, et al (1989) Weekly low-dose multidrug chemotherapy (MDCT) plus pneumocystis prophylaxis for HIV-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 8: 1

    Google Scholar 

  86. Preusser P, Wilke H, Achterrath W, et al (1989) Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310–1317

    Google Scholar 

  87. Lerner A, Steele GD, Mayer RJ (1990) Etoposide, doxorubicin, cisplatin (EAP) chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial (abstract). Proc Am Soc Clin Oncol 9: 103

    Google Scholar 

  88. Wilke H, Preusser P, Fink U, et al (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 7: 1318–1326

    Google Scholar 

  89. Kelsen D, Atiq O, Saltz L, et al (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10: 541–548

    Google Scholar 

  90. Wilke H, Preusser P, Fink U, et al (1990) High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer: a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8: 65–70

    Google Scholar 

  91. Pastan I, Gottesman MM (1987) Multi-drug resistance in human cancer. N Engl J Med 316: 1388–1393

    Google Scholar 

  92. Goldstein LJ, Galski H, Fojo A, et al (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–124

    Google Scholar 

  93. Fojo A, Ueda K, Salmon DJ, et al (1987) Expression of a multidrug-resistant gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269

    Google Scholar 

  94. Nooter K, Herweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663–669

    Google Scholar 

  95. Slater L, Sweet P, Stupecky M, et al (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in-vitro. J Clin Invest 77: 1405–1408

    Google Scholar 

  96. Willingham M, Cornwell M, Cardarelli, C et al (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46: 591–594

    Google Scholar 

  97. Cornwell M, Pastan I, Gottesman M (1987) Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 26: 2166–2170

    Google Scholar 

  98. Lum BL, Kaubisch S, Yahanda AM, et al (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635–1642

    Google Scholar 

  99. Yahanda M, Adler KM, Fisher GA, et al (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624–1634

    Google Scholar 

  100. Eckhardt JR, Burris HA, Rodriquez GA, Fields SM, et al (1993) A phase I study of topoisomerase I and II inhibitors topotecan (T) and etoposide (E) (abstract). Proc Am Soc Clin Oncol 12: 137

    Google Scholar 

  101. Doyle LA, Hamburger AW, Goldstein LH, et al (1990) Interaction of recombinant human tumor necrosis factor (TNF) and etoposide in human lung cancer cell lines. Mol Biother 2: 169–174

    Google Scholar 

  102. Doyle LA, Guangiulio D, Hussain A, et al (1989) Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. Cancer Res 49: 6745–6751

    Google Scholar 

  103. Von Hoff DD, McGill J, Davidson K, et al (1992) Preclinical leads for innovative uses of etoposide. Semin Oncol 19 [Suppl 13]: 10–13

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pittsburgh Cancer Institute, Division of Medical Oncology, University of Pittsburgh Medical Center, 200 Lothrop Street, 15213, Pittsburgh, PA, USA

    Chandra P. Belani

  2. University of Maryland Cancer Center, Baltimore, Maryland, USA

    L. Austin Doyle & Joseph Aisner

Authors
  1. Chandra P. Belani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Austin Doyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph Aisner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belani, C.P., Doyle, L.A. & Aisner, J. Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol. 34 (Suppl 1), S118–S126 (1994). https://doi.org/10.1007/BF00684875

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00684875

Key words

Search

Navigation